Sernova Corp. (SEOVF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
As of 09:56AM EDT. Market open.
| Previous Close | 0.3178 |
| Open | 0.3114 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.3114 - 0.3114 |
| 52 Week Range | 0.2900 - 0.8300 |
| Volume | |
| Avg. Volume | 21,530 |
| Market Cap | 94.481M |
| Beta (5Y Monthly) | 1.48 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0900 |
| Earnings Date | Jun 12, 2024 - Jun 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- News Direct
Sernova Welcomes Dr. Bernd Muehlenweg as Evotec's Nominee for its Board of Directors
Dr. Daniel Mahony to step down to pursue new commitment
- Baystreet
Stocks in play: Sernova Corp.
Announced the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) ...
GlobeNewswireSernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA
Sernova announces research collaboration with Professor Antonia Follenzi, expert in Hemophilia A at the University of Piemonte OrientaleLONDON, Ontario and WINDHAM COUNTY, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for the company’s Hem
© 2024 Yahoo. All rights reserved.